Enjoy a flat 15% OFF on all 2025 Global Market Reports until March 31st! Use code FY25SAVE to save big—don’t miss out!

What key factors are powering the surge in the vectibix (panitumumab) market right now?

The market for Vectibix (panitumumab) has been experiencing robust growth in the past few years. The market value is expected to surge from $1,269.97 million in 2024 to $1,373.61 million in 2025, indicating a compound annual growth rate (CAGR) of 8.2%. This substantial growth during the historical period can be linked to factors such as enhanced overall survival rates in clinical trials, beneficial reimbursement policies in advanced markets, financial assistance programs for patients, educational efforts aimed at oncologists regarding genetic testing, and broader access to cutting-edge diagnostics in developing regions.

How fast Is the vectibix (panitumumab) market expected to grow, and what’s its future value?

Expectations are high for the vectibix (panitumumab) market to experience significant enhancement in its size in the forthcoming years, projecting a growth to $1,853.91 million by 2029 and a compound annual growth rate (CAGR) of 7.8%. This anticipated growth in the forecast period is believed to be due to factors such as the growing occurrence of metastatic colorectal cancer (mcrc) worldwide, an increased emphasis on tailored medication, the surge in healthcare expenditures in burgeoning markets, a higher adoption rate of biologics in the field of oncology, and an increased focus on patient’s quality of life. The forecast period is also expected to witness major trends including advancements in anti-EGFR therapies, the forming of alliances and collaborations among pharmaceutical firms, the incorporation of revolutionary diagnostic tools, the development of companion diagnostics, and the adoption of next-generation sequencing.

Get your vectibix (panitumumab) market report here!

https://www.thebusinessresearchcompany.com/report/vectibix-panitumumab-global-market-report-

What are the leading drivers of growth in the vectibix (panitumumab) market?

The anticipated increase in colorectal cancer instances is predicted to drive the evolution of the Vectibix (panitumumab) market. Colorectal cancer, which begins in the colon or rectum, is generally influenced by genetic, lifestyle, and environmental aspects. An aging population, improved survival rates, genetic tendencies, and environmental elements contribute to the increasing incidence of this kind of cancer. Vectibix (panitumumab) is a monoclonal antibody that interferes with an epidermal growth factor receptor (EGFR), aiding in hindering tumor growth and spread in patients with wild-type KRAS tumors. It thereby provides a potent treatment alternative for those unresponsive to typical chemotherapy. As an example, the World Health Organization, a Swiss intergovernmental institution, projected in September 2022 that the global impact of colorectal cancer will substantially increase by 2040, with 3.2 million new cases annually – a 63% increase. Deaths due to colorectal cancer are also projected to grow, achieving 1.6 million per annum, marking a 73% surge. As a result, the rising prevalence of colorectal cancer is envisaged to boost the Vectibix (panitumumab) market. The escalating demand for personalized medicine is predicted to drive the evolution of the Vectibix (panitumumab) market. Personalized medicine delivers a healthcare approach that adapts treatments and strategies based on the unique features, needs, and inclinations of each patient. The growing popularity of personalized medicine results from advances in genomic technologies, deeper comprehension of molecular biology, broader availability of precision diagnostic tools, and the demand for targeted therapies to better patient outcomes while reducing side effects. Vectibix (panitumumab) caters to personalized medicine by targeting the EGFR on cancer cells, allowing for the custom treatment of patients with metastatic colorectal cancer whose tumors express wild-type EGFR. This means optimizing therapeutic efficacy and minimizing unnecessary side effects based on individual genetic profiles. The Personalized Medicine Coalition, a non-profit organization based in the United States, reported in February 2023 that the FDA’s Center for Devices and Radiological Health, in collaboration with the Center for Biologics Evaluation and Research, approved or granted clearances for significant new or expanded indications across 12 in vitro diagnostic testing applications in 2022. Consequently, the escalating demand for personalized medicine is propelling the growth of the Vectibix (panitumumab) market.

What are the key segments defining the vectibix (panitumumab) market?

The vectibix (panitumumab)market covered in this report is segmented –

1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies

2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments

3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19944&type=smp

Who are the key players steering the development of the vectibix (panitumumab) market?

Major companies operating in the vectibix (panitumumab) market include Amgen Inc.

What emerging trends are influencing the growth of the vectibix (panitumumab) market?

The dominant trend in the Vectibix (panitumumab) market involves the development of molecular diagnostic tools such as companion diagnostic kits, to deliver personalized treatment. These kits are tests created to pinpoint specific biomarkers or genetic mutations in individuals, thereby predicting the likelihood of them benefiting from specific therapeutic treatments. For example, in October 2023, the biotech company based in the U.S., EntroGen Inc., unveiled the FDA approval for their CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab). This unique, molecular diagnostic tool marks considerable progress in precise medicine for individuals dealing with colorectal cancer (CRC). The CRCdx RAS Mutation Detection Kit, which is the first-ever real-time PCR-based test to be granted premarket approval (PMA) in the U.S, fully meets the biomarker identification criteria for Vectibix. Designed to detect mutations efficiently in KRAS and NRAS exons 2, 3, and 4, this revolutionary kit exhibits high sensitivity and specificity. Through this, healthcare professionals can identify those who are most likely to benefit from Vectibix therapy, curtailing unnecessary side effects and the cost of treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19944

Which regions are most influential in expanding the vectibix (panitumumab) market?

North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vectibix (panitumumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Colorectal Cancer Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Global Colorectal Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Cancer Immunotherapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: